海外の治験の状況「COVID-19」での検索結果
70件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- New Treatment for Radical Cure of Dengue Fever with Antiviral and Anti-cytokine
- Dengue Fever Patient-3 days fever-severe body&joints pain-conjuntival congestion-retro bulbar tenderness-Rashes-headache-nausea; male,female all age. Dengue detection Elisa NS1 IgM & IgG & DENV-RTPCR
- India
- 2017-12-11
Recruiting
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
- ALK Gene Rearrangement;EGFR Exon 19 Deletion Mutation;EGFR NP_005219.2:p.L858R;Stage IB Non-Small Cell Lung Carcinoma AJCC v7;Stage II Non-Small Cell Lung Cancer AJCC v7;Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- United States
- 2014-07-15
Recruiting
- Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma;EGFR Activating Mutation;EGFR Exon 19 Deletion Mutation;EGFR NP_005219.2:p.G719X;EGFR NP_005219.2:p.L858R;EGFR NP_005219.2:p.L861Q;EGFR NP_005219.2:p.T790M;Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;Stage III Non-Small Cell Lung Cancer AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7;Stage IIIB Lung Non-Small Cell Cancer AJCC v7;Stage IV Non-Small Cell Lung Cancer AJCC v7
- United States
- 2015-08-10
Recruiting
- Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
- EGFR Activating Mutation;EGFR Exon 19 Deletion Mutation;EGFR NP_005219.2:p.G719X;EGFR NP_005219.2:p.L858R;EGFR NP_005219.2:p.L861Q;EGFR T790M Mutation Negative;Recurrent Lung Non-Small Cell Carcinoma;Stage III Non-Small Cell Lung Cancer AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7;Stage IIIB Lung Non-Small Cell Cancer AJCC v7;Stage IV Non-Small Cell Lung Cancer AJCC v7
- Canada, United States
- 2015-07-20
Recruiting
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
- EGFR Exon 19 Deletion Mutation;EGFR Exon 20 Insertion Mutation;EGFR NP_005219.2:p.G719X;EGFR NP_005219.2:p.L858R;EGFR NP_005219.2:p.L861Q;EGFR NP_005219.2:p.T790M;EGFR T790M Mutation Negative;Metastatic Lung Non-Small Cell Carcinoma;Recurrent Lung Non-Small Cell Carcinoma;Stage IV Non-Small Cell Lung Cancer AJCC v7
- United States
- 2015-07-09
Recruiting
- Sexual dysfunction and fertility-related distress in young adult survivors of childhood cancer
- Sexual dysfunction and fertility-related distress in young adult (19-40 years of age) survivors of childhood cancer (diagnosis at 0-17 years of age, including all malignant diagnoses and brain tumors) Mental and Behavioural Disorders
- Sweden
- 2019-11-27
Recruiting
- Immune Disorder HSCT Protocol
- Immune Deficiency Disorders;Severe Combined Immunodeficiency;Chronic Granulomatous Disease;X-linked Agammaglobulinemia;Wiskott-Aldrich Syndrome;Hyper-IgM;DiGeorge Syndrome;Chediak-Higashi Syndrome;Common Variable Immune Deficiency;Immune Dysregulatory Disorders;Hemophagocytic Lymphohistiocytosis;IPEX;Autoimmune Lymphoproliferative Syndrome;X-linked Lymphoproliferative Syndrome
- United States
- 2013-03-19
Recruiting
- Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
- EGFR (Epidermal Growth Factor Receptor) Exon 19 Deletion Mutation;EGFR NP_005219.2:p.L858R;EGFR NP_005219.2:p.T790M;Stage I Non-Small Cell Lung Cancer AJCC (American Joint Committee on Cancer) v7;Stage IA Non-Small Cell Lung Carcinoma AJCC v7;Stage IB Non-Small Cell Lung Carcinoma AJCC v7;Stage II Non-Small Cell Lung Cancer AJCC v7;Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- United States
- 2018-01-25
Recruiting
- Dystonia Genotype-Phenotype Correlation
- Dystonia;Dystonia; Idiopathic;Dystonia, Primary;Dystonia, Secondary;Dystonia, Familial;Dystonia Disorder;Dystonias, Sporadic;Dystonia; Orofacial;Dystonia Lenticularis;Dystonia, Paroxysmal;Dystonia 6;Dystonia 5;Dystonia 8;Dystonia 9;Dystonia 19;Dystonia 10;Dystonia 11;Dystonia 20;Dystonia 12;Dystonia, Focal;Dystonia of Head;Dystonia, Diurnal;Dystonia;Dystonia; Idiopathic;Dystonia, Primary;Dystonia, Secondary;Dystonia, Familial;Dystonia Disorder;Dystonias, Sporadic;Dystonia; Orofacial;Dystonia Lenticularis;Dystonia, Paroxysmal;Dystonia 6;Dystonia 5;Dystonia 8;Dystonia 9;Dystonia 19;Dystonia 10;Dystonia 11;Dystonia 20;Dystonia 12;Dystonia, Focal;Dystonia of Head;Dystonia, Diurnal;Dystonia;Dystonia; Idiopathic;Dystonia, Primary;Dystonia, Secondary;Dystonia, Familial;Dystonia Disorder;Dystonias, Sporadic;Dystonia; Orofacial;Dystonia Lenticularis;Dystonia, Paroxysmal;Dystonia 6;Dystonia 5;Dystonia 8;Dystonia 9;Dystonia 19;Dystonia 10;Dystonia 11;Dystonia 20;Dystonia 12;Dystonia, Focal;Dystonia of Head;Dystonia, Diurnal
- United States
- 2018-02-02
Recruiting
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
- Spectrin-associated Autosomal Recessive Cerebellar Ataxia;Spasticity-ataxia-gait Anomalies Syndrome;Spastic Ataxia With Congenital Miosis;Spastic Ataxia - Corneal Dystrophy;Spastic Ataxia;Rare Hereditary Ataxia;Rare Ataxia;Recessive Mitochondrial Ataxia Syndrome;Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;Posterior Column Ataxia - Retinitis Pigmentosa;Post-Stroke Ataxia;Post-Head Injury Ataxia;Post Vaccination Ataxia;Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;Non-progressive Cerebellar Ataxia With Intellectual Disability;Non-hereditary Degenerative Ataxia;Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;Olivopontocerebellar Atrophy - Deafness;NARP Syndrome;Myoclonus - Cerebellar Ataxia - Deafness;Multiple System Atrophy, Parkinsonian Type;Multiple System Atrophy, Cerebellar Type;Multiple System Atrophy;Maternally-inherited Leigh Syndrome;Machado-Joseph Disease Type 3;Machado-Joseph Disease Type 2;Machado-Joseph Disease Type 1;Lethal Ataxia With Deafness and Optic Atrophy;Leigh Syndrome;Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;Leigh Syndrome With Nephrotic Syndrome;Leigh Syndrome With Leukodystrophy;Leigh Syndrome With Cardiomyopathy;Late-onset Ataxia With Dementia;Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;Infection or Post Infection Ataxia;Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;Infantile Onset Spinocerebellar Ataxia;GAD Ataxia;Hereditary Episodic Ataxia;Gliadin/Gluten Ataxia;Friedreich Ataxia;Fragile X-associated Tremor/Ataxia Syndrome;Familial Paroxysmal Ataxia;Exposure to Medications Ataxia;Episodic Ataxia With Slurred Speech;Episodic Ataxia Unknown Type;Episodic Ataxia Type 7;Episodic Ataxia Type 6;Episodic Ataxia Type 5;Episodic Ataxia Type 4;Episodic Ataxia Type 3;Episodic Ataxia Type 1;Epilepsy and/or Ataxia With Myoclonus as Major Feature;Early-onset Spastic Ataxia-neuropathy Syndrome;Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;Early-onset Ataxia With Dementia;Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;Dilated Cardiomyopathy With Ataxia;Cataract - Ataxia - Deafness;Cerebellar Ataxia, Cayman Type;Cerebellar Ataxia With Peripheral Neuropathy;Cerebellar Ataxia - Hypogonadism;Cerebellar Ataxia - Ectodermal Dysplasia;Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;Brain Tumor Ataxia;Brachydactyly - Nystagmus - Cerebellar Ataxia;Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;Autosomal Recessive Syndromic Cerebellar Ataxia;Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;Autosomal Recessive Spastic Ataxia;Autosomal Recessive Metabolic Cerebellar Ataxia;Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;Autosomal Recessive Ataxia, Beauce Type;Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;Autosomal Recessive Ataxia Due to PEX10 Deficiency;Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;Autosomal Recessive Congenital Cerebellar Ataxia;Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;Autosomal Recessive Cerebellar Ataxia;Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;Autosomal Dominant Spastic Ataxia Type 1;Autosomal Dominant Spastic Ataxia;Autosomal Dominant Optic Atrophy;Ataxia-telangiectasia Variant;Ataxia-telangiectasia;Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;Autosomal Dominant Cerebellar Ataxia Type 4;Autosomal Dominant Cerebellar Ataxia Type 3;Autosomal Dominant Cerebellar Ataxia Type 2;Autosomal Dominant Cerebellar Ataxia Type 1;Autosomal Dominant Cerebellar Ataxia;Ataxia-telangiectasia-like Disorder;Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;Ataxia-deafness-intellectual Disability Syndrome;Ataxia With Vitamin E Deficiency;Ataxia With Dementia;Ataxia Neuropathy Spectrum;Ataxia - Tapetoretinal Degeneration;Ataxia - Photosensitivity - Short Stature;Ataxia - Pancytopenia;Ataxia - Oculomotor Apraxia Type 1;Ataxia - Hypogonadism - Choroidal Dystrophy;Ataxia - Other;Ataxia - Genetic Diagnosis - Unknown;Acquired Ataxia;Adult-onset Autosomal Recessive Cerebellar Ataxia;Alcohol Related Ataxia;Multiple Endocrine Neoplasia;Multiple Endocrine Neoplasia Type II;Multiple Endocrine Neoplasia Type 1;Multiple Endocrine Neoplasia Type 2;Multiple Endocrine Neoplasia, Type IV;Multiple Endocrine Neoplasia, Type 3;Multiple Endocrine Neoplasia (MEN) Syndrome;Multiple Endocrine Neoplasia Type 2B;Multiple Endocrine Neoplasia Type 2A;Atypical Hemolytic Uremic Syndrome;Atypical HUS;Wiedemann-Steiner Syndrome;Breast Implant-Associated Anaplastic Large Cell Lymphoma;Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);Hemophagocytic Lymphohistiocytosis;Behcet's Disease;Spinocerebellar Ataxia Type 17;Spinocerebellar Ataxia Type 16;Spinocerebellar Ataxia Type 15/16;Spinocerebellar Ataxia Type 14;Spinocerebellar Ataxia Type 13;Spinocerebellar Ataxia Type 12;Spinocerebellar Ataxia Type 11;Spinocerebellar Ataxia Type 10;Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;Spinocerebellar Ataxia Type 1;Spinocerebellar Ataxia - Unknown;Spinocerebellar Ataxia - Dysmorphism;Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;Alagille Syndrome;Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);Lowe Syndrome;Pitt Hopkins Syndrome;1p36 Deletion Syndrome;Jansen Type Metaphyseal Chondrodysplasia;Cockayne Syndrome;Chronic Recurrent Multifocal Osteomyelitis;CRMO;Malan Syndrome;Hereditary Sensory and Autonomic Neuropathy Type Ie;Rare Disorders;Undiagnosed Disorders;Disorders of Unknown Prevalence;Cornelia De Lange Syndrome;Prenatal Benign Hypophosphatasia;Perinatal Lethal Hypophosphatasia;Odontohypophosphatasia;Adult Hypophosphatasia;Childhood-onset Hypophosphatasia;Infantile Hypophosphatasia;Hypophosphatasia;Kabuki Syndrome;Bohring-Opitz Syndrome;Narcolepsy Without Cataplexy;Narcolepsy-cataplexy;Hypersomnolence Disorder;Idiopathic Hypersomnia Without Long Sleep Time;Idiopathic Hypersomnia With Long Sleep Time;Idiopathic Hypersomnia;Kleine-Levin Syndrome;Kawasaki Disease;Leiomyosarcoma;Leiomyosarcoma of the Corpus Uteri;Leiomyosarcoma of the Cervix Uteri;Leiomyosarcoma of Small Intestine;Acquired Myasthenia Gravis;Addison Disease;Hyperacusis (Hyperacousis);Juvenile Myasthenia Gravis;Transient Neonatal Myasthenia Gravis;Williams Syndrome;Lyme Disease;Myasthenia Gravis;Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);Isolated Klippel-Feil Syndrome;Frasier Syndrome;Denys-Drash Syndrome;Beckwith-Wiedemann Syndrome;Emanuel Syndrome;Isolated Aniridia;Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;Axenfeld-Rieger Syndrome;Aniridia-intellectual Disability Syndrome;Aniridia - Renal Agenesis - Psychomotor Retardation;Aniridia - Ptosis - Intellectual Disability - Familial Obesity;Aniridia - Cerebellar Ataxia - Intellectual Disability;Aniridia - Absent Patella;Aniridia;Peters Anomaly - Cataract;Peters Anomaly;Potocki-Shaffer Syndrome;Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;Silver-Russell Syndrome Due to Imprinting Defect of 11p15;Silver-Russell Syndrome Due to 11p15 Microduplication;Syndromic Aniridia;WAGR Syndrome;Wolf-Hirschhorn Syndrome;4p16.3 Microduplication Syndrome;4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;Autosomal Recessive Stickler Syndrome;Stickler Syndrome Type 2;Stickler Syndrome Type 1;Stickler Syndrome;Mucolipidosis Type 4;X-linked Spinocerebellar Ataxia Type 4;X-linked Spinocerebellar Ataxia Type 3;X-linked Intellectual Disability - Ataxia - Apraxia;X-linked Progressive Cerebellar Ataxia;X-linked Non Progressive Cerebellar Ataxia;X-linked Cerebellar Ataxia;Vitamin B12 Deficiency Ataxia;Toxic Exposure Ataxia;Unclassified Autosomal Dominant Spinocerebellar Ataxia;Thyroid Antibody Ataxia;Sporadic Adult-onset Ataxia of Unknown Etiology;Spinocerebellar Ataxia With Oculomotor Anomaly;Spinocerebellar Ataxia With Epilepsy;Spinocerebellar Ataxia With Axonal Neuropathy Type 2;Spinocerebellar Ataxia Type 8;Spinocerebellar Ataxia Type 7;Spinocerebellar Ataxia Type 6;Spinocerebellar Ataxia Type 5;Spinocerebellar Ataxia Type 4;Spinocerebellar Ataxia Type 37;Spinocerebellar Ataxia Type 36;Spinocerebellar Ataxia Type 35;Spinocerebellar Ataxia Type 34;Spinocerebellar Ataxia Type 32;Spinocerebellar Ataxia Type 31;Spinocerebellar Ataxia Type 30;Spinocerebellar Ataxia Type 3;Spinocerebellar Ataxia Type 29;Spinocerebellar Ataxia Type 28;Spinocerebellar Ataxia Type 27;Spinocerebellar Ataxia Type 26;Spinocerebellar Ataxia Type 25;Spinocerebellar Ataxia Type 23;Spinocerebellar Ataxia Type 22;Spinocerebellar Ataxia Type 21;Spinocerebellar Ataxia Type 20;Spinocerebellar Ataxia Type 2;Spinocerebellar Ataxia Type 19/22;Spinocerebellar Ataxia Type 18
- Australia, United States
- 2013-02-13
